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Abstract The risk of nutrient deficiencies increases with
age in our modern Western society, and vitamin B12 defi-
ciency is especially prevalent in the elderly and causes
increased homocysteine (Hcy) and methylmalonic acid
(MMA) levels. These three factors have been recognized as
risk factors for reduced bone mineral density and increased
fracture risk, though mechanistic evidence is still lacking. In
the present study, we investigated the influence of B12, Hcy,
and MMA on differentiation and activity of bone cells.
B12 deficiency did not affect the onset of osteoblast differ-
entiation, maturation, matrix mineralization, or adipocyte
differentiation from human mesenchymal stem cells
(hMSCs). B12 deficiency caused an increase in the secretion
of Hcy and MMA into the culture medium by osteoblasts,
but Hcy and MMA appeared to have no effect on hMSC
osteoblast differentiation. We further studied the effect of
B12, Hcy, and MMA on the formation of multinucleated
tartrate-resistant acid phosphatase–positive osteoclasts from
mouse bone marrow. We observed that B12 did not show an
effect on osteoclastogenesis. However, Hcy as well as
MMA were found to induce osteoclastogenesis in a
dose-dependent manner. On the basis of these results, we
conclude that B12 deficiency may lead to decreased bone
mass by increased osteoclast formation due to increased
MMA and Hcy levels.
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Osteoporosis is a complex multifactorial disease with a
strong genetic component, but lifestyle factors are also
important for maintenance of bone mass. Nutrition is one
of the factors that contributes to bone health. During the
first decades of life, adequate intake of calcium and vitamin
D is essential to establish peak bone mass (see [1, 2] and
references therein). It has also been observed that nutri-
tional deficiencies can cause impaired growth and skeletal
abnormalities during childhood [3], while in adults inade-
quate intake of nutrients such as proteins, vitamins, and
minerals has been associated with loss of bone quality [2,
4]. Nutritional deficiency is very common in the elderly,
emphasizing that adequate nutrient intake may slow down
the age-related loss of bone mass.
A challenge in nutrition research is to identify food
components that contribute to the maintenance of bone
health. During the last years, vitamin B12 has gained par-
ticular attention since a number of epidemiological studies
have reported a correlation between B12 status and bone
quality and fracture risk [5–9]. The micronutrient B12 is
involved as a cofactor in two enzymatic reactions [10]. The
enzyme methionine synthase requires B12 for the remethy-
lation of homocysteine (Hcy) into methionine. The other
enzyme dependent on B12 is methylmalonyl-CoA mutase,
which catalyzes the conversion of methylmalonyl-CoA into
succinyl-CoA. As a consequence of B12 deficiency, these
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enzymatic reactions are impaired and Hcy and methylma-
lonic acid (MMA) accumulate [11].
In the elderly, B12 uptake is reduced and the prevalence
of low B12 levels as well as moderate hyperhomocystein-
emia and elevated serum MMA levels increases with age
[12]. Several studies have reported that low plasma B12
levels are associated with reduced bone quality [5, 8, 9, 13,
14], but this relation has not been observed by others
[15–17]. More consistently, however, are the observations
that increased Hcy may be a predictive factor for fracture
risk [13–15, 18–21]. Also, elevated MMA levels have been
associated with osteoporosis in the elderly [14] and low
bone mineral density (BMD) in adolescents [6]. Together,
these data suggest that B12, Hcy, and MMA are important
factors in the development of osteoporosis.
The mechanisms by which B12 deficiency leads to
impaired bone quality are still poorly understood. A
number of studies have described the effects of B12 and
Hcy on osteoblasts and osteoclasts [22–27]. Here, we
analyzed the effects of B12, Hcy, and MMA on human
mesenchymal stem cells (hMSCs), the precursor cells of
both osteoblasts and adipocytes. In theory, a number of
mechanisms may underlie the reduced bone quality in
cases of B12 deficiency. B12 may have a stimulatory effect
on bone formation via enhanced osteoblast differentiation
or improved bone matrix mineralization. B12 may also act
in a negative way on osteoclast formation and function. It
can be hypothesized that Hcy and MMA may act in an
opposite manner, i.e., reduced osteoblast formation and
increased osteoclast formation. In the present study we
examined the effects of varying levels of B12, Hcy, and
MMA on the differentiation of MSCs into osteoblasts as
well as on osteoclastogenesis from bone marrow cultures.
Materials and Methods
Cell Culture
hMSCs were obtained from Lonza (Verviers, Belgium; male
donors, lot numbers 6F3502 and 6F4392) and cultured in
proliferation medium as supplied by the manufacturer.
Murine MC3T3-E1 osteoblast precursor cell, obtained from
the American Type Culture Collection (Manassas, VA),
were maintained in a-MEM supplemented with 10% fetal
bovine serum (FBS, Lonza), penicillin (100 U/ml), and
streptomycin (100 lg/ml). Cells were maintained at 37C in
a humidified atmosphere containing 5% CO2. For differen-
tiation experiments, cells were seeded at a density of
1.0 9 104/cm2 in proliferation medium. Two days after cell
seeding, the medium was replaced with osteogenic or adi-
pogenic differentiation medium. Osteogenic medium for
hMSCs consisted of DMEM (Lonza) supplemented with
10% FBS, penicillin/streptomycin, L-glutamine, 100 nM
dexamethasone, 50 lg/ml ascorbic acid, 10 nM vitamin D,
and 12.5 mM b-glycerophosphate. Osteogenic medium for
MC3T3-E1 cells consisted of DMEM/10% FBS supple-
mented with penicillin/streptomycin, L-glutamine, 50 lg/ml
ascorbic acid, and 12.5 mM b-glycerophosphate.
The DMEM medium did not contain B12 according to
the manufacturer’s specification sheet. Determination of
B12 levels (Lab SHO, Velp, The Netherlands) in DMEM
was below the detection limit of 40 pM, while FBS con-
tained 125 pM B12.
Cells were cultured in osteogenic medium (B12-defi-
cient) or osteogenic medium supplemented with B12
mimicking physiological levels (500 pM) or high-B12
supplementation (50 nM). Adipogenic differentiation was
stimulated by culturing cells in DMEM/10% FBS supple-
mented with penicillin/streptomycin, L-glutamine, 1 lM
dexamethasone, 1 lM rosiglitazone, 0.45 mM isobutylm-
ethylxanthine, and 5 lg/ml insulin. During differentiation,
the medium was refreshed twice a week.
DL-Homocysteine, B12 (cyanocobalamin), and MMA
were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands).
Alkaline Phosphatase Assays
Alkaline phosphatase (ALP) cytochemical staining was
performed using the Alkaline Phosphatase Sigma Diag-
nostics kit 85, according to the protocol supplied by the
manufacturer. ALP activity was determined by measuring
the formation of p-nitrophenol from p-nitrophenyl phos-
phate (PNPP, Sigma-Aldrich). Briefly, cells were cultured
in 96-well plates, washed twice with PBS, and fixed in 4%
paraformaldehyde/PBS for 10 minutes at 4C. Subse-
quently, cells were incubated with PNPP for 15 minutes at
37C, after which the reaction was terminated with NaOH
and the absorbance of p-nitrophenol was measured at
414 nm. ALP activity was corrected for cell number as
determined by a neutral red assay. Cells were incubated
with neutral red dye diluted in PBS for 1 hour at 37C.
After washing with PBS, the dye was extracted from the
cells with 0.05 M NaH2PO4 in 50% EtOH and absorbance
was measured at 540 nm. The results of the neutral red
assay revealed that cell numbers were not changed by the
different culture conditions. Measurements were performed
sixfold and averaged.
Mineralization Assays
Calcium concentrations were determined in a colorimetric
assay with o-cresolphthalein complexone as a chromogenic
agent. Cells were washed twice with PBS, after which
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calcium was extracted with 0.5 M HCl by incubating
overnight with continuous shaking.
Calcium was quantified by mixing 50 ll of sample with
950 ll of assay solution containing calcium binding
reagent (0.024wt% o-cresolphthalein and 0.25wt% 8-hy-
droxyquinone in H2O) and calcium buffer (500 mM 2-
amino-2-methyl-1,3 propanediol in H2O) in a 1:1 volume
mixture. The absorbance of each solution was measured at
575 nm. All reagents were obtained from Sigma-Aldrich.
Triglyceride Analysis
For quantification of lipid accumulation during adipogen-
esis, cells were grown in 24-well plates. Cells were washed
twice with PBS, after which lipids were extracted by
shaking for 10 minutes in 50 ll of 25 mM Tris–HCl
(pH7.5)/1 mM EDTA, 40 ll of tert-butanol, and 10 ll of
methanol. After drying the plates, triglycerides were
determined spectrophotometrically using the triglyceride
Liquicolor Monoreagent (Instruchemie, Delfzijl, The
Netherlands). Triglyceride formation was expressed as fold
changes averaged over biological duplicate measurements.
The accumulation of lipid droplets during adipogenic
differentiation was visualized by staining with oil red O
(ORO) in combination with ALP staining as described
above. After staining for ALP, cells were washed twice
with water and incubated with ORO staining solution
containing two volumes of 50 mg ORO in 10 ml isopro-
panol and three volumes of water. After staining for
10 minutes at 37C, cells were washed twice with water
and pictures were taken.
RNA Isolation and Real-Time PCR
Total RNA was extracted from cells using TRIzol
Reagent (Invitrogen, Breda, The Netherlands), and RNA
concentrations were determined by measuring the absor-
bance at 260 nm.
Total RNA (1 lg) was reverse-transcribed with the use of
the cDNA synthesis kit (Promega, Leiden, the Netherlands).
Subsequently, cDNA was amplified in a quantitative real-
time PCR performed with the use of Platinum Taq DNA
polymerase (Invitrogen) and SYBR green on an iCycler
PCR machine (Bio-Rad, Veenendaal, The Netherlands). The
data were normalized by measuring threshold cycle ratios
between the candidate genes and a housekeeping gene,
RPS27A (ribosomal protein S27a). The following primer
pairs were used: RPS27A (forward), GTTAAGCTGGCTGT
CCTGAAA, RPS27A (reverse), CATCAGAAGGGCACTC
TCG; ALP (forward), GATGGACAAGTTCCCCTTCGT,
ALP (reverse), GGACCTGGGCATTGGTGTT; COL1A1
(forward), GTCGAGGGCCAAGACGAAG, COL1A1
(reverse), CAGATCACGTCATCGCACAAC; IBSP
(forward), GCAAAATTAAAGCAGTCTTCATTTTG, IBSP
(reverse), TGCCTTGAGCCTGCTTCC; OPG (forward),
AAGGGCGCTACCTTGAGATAG, OPG (reverse), GCA
AACTGTATTTCGCTCTGGG.
Osteocalcin Assay
Osteocalcin in cultured medium form murine MC3T3-E1
cells was determined by an immunoradiometric assay
(Immutopics, San Clemente, CA). The detection limit is
29 ng/ml, intra-assay variation is 4.55%, and interassay
variation is 6.1%.
Determination of Hcy and MMA Levels
Total Hcy levels secreted by hMSCs and MC3T3 cells
were determined in the cell culture medium by an auto-
mated HPLC method with reverse-phase separation and
fluorescent detection as described earlier [28]. MMA con-
centrations in the culture medium were measured with the
use of a liquid chromatography mass spectrometry method
(LC-MS-MS).
Osteoclastogenesis
Osteoclast differentiation from bone marrow cultures was
performed as described previously [29]. Whole bone mar-
row isolated from femurs of male C56/BL6 mice was
cultured in 96-well plates at a density of 1.0 9 105 cells/
well on plastic and on 650-lm-thick bovine cortical long
bone slices. Cells on plastic were cultured in 150 ll of
DMEM/5% FBS medium containing 30 ng/ml recombi-
nant murine M-CSF (R&D Systems, Minneapolis, MN)
and 20 ng/ml RANKL (Biovision, Mountain View, CA) to
induce osteoclast formation. Cells on bone slices were
cultured in 150 ll a-MEM/5% FCS supplemented with
30 ng/ml M-CSF and 20 ng/ml recombinant mouse
RANKL (R&D Systems). Cells were cultured for 7 or
9 days in the presence of B12, Hcy, or MMA on plastic or
for 6 days on bone slices. The medium was refreshed after
3 and 6 days. RANKL (Biovision) was kindly provided by
Dr. R. Arends (Organon, Oss, The Netherlands).
Tartrate-Resistant Acid Phosphatase Assay
Osteoclast cultures were washed with PBS, fixed, and
stained for tartrate-resistant acid phosphatase (TRAP)
using the Sigma-Aldrich Acid Phosphatase Kit 387,
according to the protocol supplied by the manufacturer.
After staining, TRAP-positive cells with three or more
nuclei were counted and pictures were taken. Student’s
t-tests (two-tailed) were carried out to compare values
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between two groups. Differences between groups were
considered significant at P \ 0.05 (two-tailed).
Results
Vitamin B12 Deficiency Does Not Affect Osteoblast
Differentiation
To examine the effect of B12 deficiency on MSC differen-
tiation, bone marrow–derived hMSCs were used since these
cells have been described as multipotent cells which effi-
ciently differentiate toward the osteoblast and adipocyte
lineage [30, 31]. We first investigated the effect of B12 on the
onset of osteoblast differentiation as characterized by
expression of ALP [32]. To exclude the possibility that
substantial baseline levels of B12 were present in the culture
medium, a quantitative measurement of B12 levels was
carried out. Baseline levels were lower than 15 pM, which is
far below the B12 deficiency level of 200 pM [13]. Culturing
hMSCs in osteogenic differentiation medium resulted in a
homogeneous population of ALP-positive cells after 9 days
of culture, as visualized by cytochemical staining for ALP
(Fig. 1a). Supplementation with 50 nM B12 had no effect on
osteoblast formation from hMSCs when characterized by
cytochemical staining. An identical result was observed with
physiological concentration of 500 pM (not shown). Simi-
larly, a quantitative assay revealed a strong induction of ALP
activity in osteogenic medium compared to control medium,
but no effect of B12 on ALP activity was detected (Fig. 1b),
even when cells were treated with concentrations up to 5 lM
(not shown). ALP activity was not changed by B12 by
repeating the experiment with cells obtained from another
donor (not shown).
To study the effect of B12 on an alternative differenti-
ation pathway of hMSCs, these cells were cultured in
adipogenic medium and triglyceride content was deter-
mined after 7 and 9 days of differentiation (Fig. 1c). A
strong increase in triglyceride formation was observed in
adipogenic medium compared to control medium, but the
triglyceride content was not significantly changed when
B12 was supplied to the medium. These data show that the
onset of hMSC differentiation toward osteoblasts or adi-
pocytes is not influenced by B12 deficiency.
We further examined the effect of B12 on osteoblast
maturation by measuring calcium deposition in the extra-
cellular matrix after 7, 9, and 11 days of differentiation.
The data presented in Fig. 1d show that hMSCs strongly
accumulated calcium in the matrix under osteogenic con-
ditions. B12 supplementation of 0.5 or 50 nM had no effect
on calcium levels, a result that was verified by means of a
von Kossa staining (not shown), indicating that B12 has no
effect on matrix mineralization.
To analyze B12 effects in more detail, osteoblast gene
expression was determined by means of quantitative real-
time PCR (Q-PCR). Expression of the osteoblast marker
genes ALP, COL1A1 (collagen type 1 alpha 1), IBSP
(integrin-binding sialoprotein or bone sialoprotein), and
OPG (osteoprotegerin) was determined in cells cultured for
2, 4, 7, and 9 days in control medium, osteogenic medium,
or osteogenic medium supplemented with 50 nM B12.
Figure 1e shows that the mRNA levels of these genes
increased in osteogenic medium but that gene expression
was not modulated by B12 supply.
Taken together, these results show that B12 has no effect
on osteoblast differentiation of hMSCs. To exclude a cell
type–specific effect, the murine preosteoblast cell line
MC3T3-E1 was tested for its response to B12. Figure 1f
shows that ALP activity was induced in osteogenic med-
ium after 4 days but, as in hMSCs, no effect of B12 could
be detected, indicating that B12 had no effect on the early
phase of MC3T3-E1 differentiation. As a marker for
osteoblast maturation, secreted osteocalcin levels were
determined in the medium of differentiating MC3T3 cells.
As can be seen in Fig. 1g, osteocalcin secretion was
strongly increased in osteogenic medium compared with
control medium during a 3-week culturing period. How-
ever, no changes in osteocalcin secretion were detected
under the influence of different B12 levels.
Vitamin B12 Deficiency Increases Hcy and MMA
Secretion by Osteoblasts
To investigate whether B12 deficiency correlates with Hcy
and MMA secretion by osteoblasts, total Hcy (tHcy) and
MMA secreted in the culture medium were measured during
osteoblast differentiation of hMSCs and MC3T3-E1 cells
(Fig. 2). As can be seen in Fig. 2a, tHcy secreted by hMSCs
in osteogenic medium increased during a differentiation
period of 10 days. After 10 days of differentiation, secreted
tHcy levels were reduced by 20% when the cells were cul-
tured in the presence of 50 nM B12. This result shows that
lower B12 levels result in higher tHcy secretion by osteo-
blasts. As in hMSCs, lowering B12 levels caused increased
tHcy secretion by MC3T3-E1 (Fig. 2b). During a 20-day
period of differentiation, a dose-dependent increase in tHcy
secretion was observed when cultures were treated with 50,
0.5, or 0 nM B12.
Secretion of MMA in the culture medium of hMSCs
appeared to be unchanged by varying B12 levels during a
differentiation period of 10 days (Fig. 2c). In MC3T3-E1
cells, however, secreted MMA levels showed a dose-
dependent response to B12 (Fig. 2d). MMA secretion was
attenuated in the presence of 0.5 and 50 nM B12, and the
effect increased during the progress of differentiation. The
observed differences between supplementation of 0 and
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Fig. 1 The effect of B12 on MSC differentiation. a Cytochemical
analysis of ALP expression in hMSCs cultured in control medium, in
osteogenic differentiation medium (OB), or in OB supplemented with
50 nM B12 for 4, 7, and 9 days. b Quantification of ALP expression in
hMSCs cultured in OB medium supplemented with B12. Measure-
ments were performed sixfold, averaged, and normalized for cell
numbers by a neutral red assay. Error bars indicate standard deviation.
c Triglyceride formation by hMSCs was quantified after 7 (white
bars) and 9 (dashed bars) days of differentiation in control medium,
adipogenic differentiation (AD) medium, or AD medium supple-
mented with B12. Triglyceride formation is represented as fold change
relative to control at t7 and t9. Adipocyte formation at t7 was
indicated by the accumulation of lipid droplets that stain with oil red
O (inset). d Calcium release by hMSCs after 7, 9, or 11 days of
culture in OB medium supplemented with 0, 0.5, or 50 nM B12.
Calcium was determined in a colorimetric reaction and quantified by
measuring the absorbance at 575 nm. e Gene expression levels of
osteoblast markers ALP, COL1A1, IBSP, and OPG in hMSCs cultured
over a period of 9 days in control medium (r), OB medium (j), or
OB medium supplemented with 50 nM B12 (m). Measurements were
performed in duplicate, after which relative expression was calculated
by correction for expression of the housekeeping gene RPS27A. f
ALP activity of murine MC3T3 osteoblast precursor cells in control
medium, OB medium, or OB supplemented with B12 over a period of
4 days. g Osteocalcin secretion in culture medium by MC3T3 cells
cultured for a period of 20 days in control medium (r), OB medium
(j), or OB medium supplemented with 0.5 nM B12 (•) or 50 nM B12
(m)
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0.5 nM B12 indicate that prolonged B12 deficiency results
in increased Hcy and MMA secretion by osteoblasts.
Hcy and MMA Do Not Reduce Osteoblast
Differentiation
To analyze the effect of Hcy on the onset of osteoblast dif-
ferentiation, ALP activity was determined in hMSCs cultured
in osteogenic medium in the presence of different concen-
trations of Hcy. Figure 3a shows that Hcy concentration up to
500 lM had no effect on ALP activity after 4 days of differ-
entiation. Also, no effect was found at other time points (data
not shown). We further investigated the effect of Hcy on
mineral deposition by differentiating hMSCs. Quantification
of the amount of calcium released from the extracellular
matrix revealed no difference due to the presence of an
increasing amount of Hcy (Fig. 3b), and an identical result
was obtained by von Kossa staining (not shown).
To study the effect of MMA levels on osteoblast dif-
ferentiation, ALP activity was analyzed in hMSCs after
4 days of differentiation (Fig. 3c). Similar to the results
obtained with Hcy, no effect of MMA on ALP activity was
observed, indicating that Hcy and MMA do not modulate
osteoblast differentiation of MSCs.
Hcy and MMA Stimulate Osteoclastogenesis
We next examined the effects of B12, Hcy, and MMA on
the formation of osteoclasts from whole bone marrow
cultures. To characterize the effect of these molecules on
osteoclast formation, multinucleated TRAP-positive cells
were counted and shown as average number of osteoclasts
per well. B12 was found to have no effect on the formation
of multinucleated TRAP-positive cells (Fig. 4a). However,
supplementation with Hcy resulted in a dose-dependent
increase in osteoclast formation (Fig. 4a). A low dose of
5 lM Hcy already led to a 2.2-fold increase in the average
number of multinucleated osteoclasts per well. The number
of osteoclasts further increased with higher concentrations
of Hcy, showing a significant increase (P \ 0.05) at 50 lM
Hcy (Fig. 4a). A very strong increase was observed in the
presence of 500 lM Hcy (Fig. 4a, b). Similar to Hcy, an
increase in osteoclast numbers was observed when cells
were cultured in the presence of MMA (Fig. 4c). These
data therefore show that both Hcy and MMA are able to
increase osteoclast formation. To analyze whether these
effects of Hcy and MMA could be observed on osteoclast
formation in a more physiological situation, bone marrow
cells were cultured on bone slices. As can be seen in
Fig. 4d, a dose of 200 lM Hcy stimulated osteoclast for-
mation. While MMA was able to increase osteoclast
formation on plastic, the effect on bone slices was not
significant at a concentration of 200 lM MMA.
We finally examined whether B12 supplementation
affects osteoclastogenesis in case of increased Hcy (Fig. 4e).
A dose of 100 lM Hcy caused a significant induction of
osteoclast formation, which was not seen when 50 nM B12
was added. Thus, while under standard culture conditions
B12 had no effect on osteoclast formation, B12 was able to
reduce the Hcy-induced osteoclastogenesis.
Fig. 2 The effect of B12 on Hcy
and MMA secretion by
osteoblasts. tHcy and MMA
levels were determined during
differentiation of hMSCs (a, c)
and MC3T3 cells (b, d) for a
period of 10 and 20 days,
respectively. tHcy and MMA
were determined at the indicated
time points and are shown as
cumulative values. Cells were
cultured in OB medium (r),
or OB medium supplemented
with 0.5 nM B12 (j)
or 50 nM B12 (m)
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Discussion
We and others have previously shown that B12 deficiency
and increased Hcy and MMA levels are associated with
impaired bone health in the elderly [6, 8, 9, 14, 21]. In order
to elucidate the molecular mechanism behind these clinical
observations, we now examined the effects of B12, Hcy, and
MMA on the differentiation of bone marrow cell cultures.
Our study is the first that has analyzed the effects of B12,
Hcy, and MMA on MSC differentiation. A number of
previous studies have appeared with contradictory results
with respect to the effect of B12 on other osteoblast model
systems. A stimulating effect on ALP expression was
reported in human rib–derived osteoprogenitors [25], rat
osteosarcoma cells [25], and chicken calvaria–derived
osteoblasts [22]. More recently, it was shown that simul-
taneous reduction of B12, B6, and folic acid levels had no
influence on ALP expression in human osteoblasts [24].
Since MSCs are a more relevant model system to cover
all stages of osteoblast differentiation, we extensively
studied the effect of B12 on these cells. Furthermore, we
used mouse MC3T3 osteoblasts to study the effect of B12
on cells which are at a later stage of osteoblast differenti-
ation. We found that B12 (1) did not affect the onset of
osteoblast differentiation, (2) did not alter the stem cell
switch, (3) did not affect matrix protein formation, and (4)
did not affect matrix calcification. However, B12 signifi-
cantly reduced Hcy and MMA secretion by differentiating
osteoblasts. Importantly, increased Hcy and MMA had no
effect on osteoblast differentiation or function, indicating
that B12 deficiency neither directly nor indirectly alters
bone formation by osteoblasts.
Based on these results, it is reasonable to expect that the
B12-associated bone loss as observed in clinical studies is
mediated by osteoclasts. Indeed, we have found that ele-
vated levels of Hcy as well as MMA had a stimulatory
effect on the formation of multinucleated TRAP-positive
osteoclasts. In contrast, various levels of B12 did not affect
the formation of osteoclasts. Gene expression analysis in
osteoblasts revealed that OPG expression was not affected
by B12, while expression of RANKL could not be detected
in hMSCs (data not shown). Our data are therefore in
agreement with a study in which no relation was found
between Hcy levels and OPG and RANKL in peri- and
postmenopausal women [33]. As OPG and RANKL are
known to regulate osteoclastogenesis, these results imply
that B12 deficiency does not indirectly affect osteoclast
formation via RANKL and OPG secretion. Together, our
data suggest a mechanism by which B12 deficiency leads to
increased Hcy and MMA levels in the bone microenvi-
ronment, thereby stimulating the formation of osteoclasts.
Fig. 3 The effect of Hcy and MMA on osteoblast differentiation.
Quantification of ALP activity in hMSCs in OB medium supple-
mented with Hcy (a) or MMA (c) after 4 days of differentiation.
Measurements were performed sixfold, averaged, and normalized for
cell numbers by a neutral red assay. b Calcium release assay by
hMSCs after 10 days (white bars) and 12 days (hatched bars). Cells
were cultured in OB medium in the presence of Hcy 0–500 lM.
Calcium was determined in a colorimetric reaction and quantified by
measuring the absorbance at 575 nm. Error bars indicate standard
deviation (n = 4)
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The effect of MMA on osteoclastogenesis has not been
described to date. The stimulatory effect of low concen-
trations of Hcy on osteoclast formation is in agreement
with a study by Koh and colleagues [26]. These data
provide in vitro support for our previous observations that
low B12 levels (\200 pM) and increased Hcy ([15 lM) in
women result in elevation of urinary secreted deoxypyri-
dinoline levels, which is a marker for collagen degradation,
Fig. 4 The effects of B12, Hcy, and MMA on osteoclast formation.
Mouse bone marrow cells cultured with M-CSF and RANKL were
treated with different concentrations of B12, Hcy, and MMA. After
TRAP staining, TRAP-positive multinucleated (n [ 2) cells (MNCs)
were counted. a Number of MNCs per well in 96-well plates after
7 days of culture (n = 6 mice, average number of MNCs). Hcy
showed a significant induction of MNCs at 50 lM (*P \ 0.05,
**P \ 0.005) and higher concentrations. b Formation of MNCs in the
presence of high B12 and Hcy concentration. Arrows indicate TRAP-
positive MNCs. Note that at 500 lM Hcy the number of nuclei per
cell is strongly increased. c Number of MNCs per well in the presence
of MMA (n = 6 mice, each measurement performed in duplicate,
9 days of culture). d Osteoclasts per millimeter squared on bone slices
(n = 5 mice, each measurement performed in duplicate, 6 days of
culture). e Reduction of Hcy-induced osteoclast formation by B12
(n = 6 mice, 9 days of culture). Error bars indicate standard error of
the mean
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a measure for bone resorption [13]. Our data indicate that
not only Hcy but also MMA may contribute to bone loss in
case of B12 deficiency.
Our study implies that, with respect to clinical applica-
tions, B12 may reduce osteoclast formation in case of high
Hcy concentrations and that reduction of Hcy and MMA
levels may be a promising strategy to prevent the increased
fracture risk in the elderly. Animal studies in mice and rats
have already revealed that modulating Hcy levels by means
of methionine-enriched diets caused an increase in bone
resorption [34, 35], indicating that nutrient intervention can
modulate bone resorption via alteration of Hcy levels. In
the elderly, Hcy levels can effectively be reduced by means
of B12 and folate supplementation [36–38]. The novel
observation that MMA is also able to induce osteoclast
formation indicates that not only Hcy but also MMA levels
need to be attenuated in order to prevent osteoporosis via
nutrient supplementation. It has previously been shown that
B12 supplementation leads to a reduction in plasma MMA
levels in elderly with B12 deficiency [36, 39]. To date,
studies on the effect of B12 and/or folate supplementation
on bone health are limited. BMD and bone formation
markers were found to increase in a group of osteoporotic
patients after 6 months of B12 and calcium supplementa-
tion [40]. A larger study in patients after stroke showed that
Hcy levels, fracture risk, and BMD were reduced after
treatment with B12 and folate for 2 years [41]. However,
another study reported that reduction of Hcy levels via B12
supplementation in healthy elderly appeared to have no
effect on markers of bone turnover in a 2-year study [42].
Two-month supplementation with folate in healthy indi-
viduals led to a decrease in Hcy, but no effect on bone
turnover markers was found [43]. Thus, the results of these
clinical studies and observations are still inconclusive with
respect to the effectiveness of B12 supplementation in
maintaining bone health.
It will be of most relevance to examine whether
reducing Hcy and MMA in a normal aging population may
prevent the occurrence of osteoporosis. Further research
and intervention studies will be required to determine to
what extent B12 and folate supplementation may prevent
bone loss by reducing Hcy- and MMA-induced osteoclast
activity during aging and in case of B12 deficiency.
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